GLP-1 genetic testing: what can a pharmacogenetic test tell you about Ozempic, Wegovy and Mounjaro?
Share
Key takeaways
- Can a genetic test tell you which GLP-1 drug or dose is right for you? Not yet. GLP-1 drugs such as Ozempic, Wegovy and Mounjaro are used for type 2 diabetes and weight loss. Some companies sell genetic tests for them, but no test has been proven to help choose the drug or the dose.
- Currently tested variants in the GLP-1 target genes play a small role. Studies have found a few gene differences linked to how much weight people lose, how much their blood sugar improves, and whether they feel sick to their stomach (nausea). The effects are small and not reliable enough to guide treatment.
- Your treatment plan matters more than these gene variants. Which drug you take, how quickly the dose is increased, and your diet and exercise make a much bigger difference.
- These tests cannot predict serious side effects. Current tests do not predict rare but serious problems such as inflammation of the pancreas (pancreatitis), thyroid cancer or vision loss.
- What helps today: increasing the dose slowly, advice on diet, regular exercise and check-ins with your prescriber or pharmacist.
Many companies now sell pharmacogenetic tests for GLP-1 receptor agonists (GLP-1RAs), the class of weight-loss and diabetes medications that includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda) and tirzepatide (Mounjaro, Zepbound). These drugs reduce appetite and slow gastric emptying. Recent genetic studies have linked variations in the GLP1R and GIPR genes to weight loss and to nausea and vomiting, the most common side effects.
Can these findings guide prescribing and dosing, or tell you which GLP-1 drug will work best for you? This article explains what GLP-1 genetic testing can and cannot tell you today, and where its benefits are modest.
Why is GLP-1 genetic testing getting so much attention?
Ozempic and Mounjaro were originally developed and approved to manage type 2 diabetes (T2D). Their expansion to weight loss created overwhelming demand and high costs for health plans, and many plans now limit coverage to people with T2D. Some insurers are considering whether genetic testing could help determine eligibility.
Employer coverage in the United States shows how quickly this is changing. A Business Group on Health survey found that the share of US employers covering GLP-1 drugs for weight loss fell from 72% to 60% in one year, and 14% have dropped or plan to drop this coverage. Starbucks is ending coverage for weight loss, and Cigna cut it for its own employees, prompting a petition signed by 450 staff. Walmart is taking a different approach: according to Bloomberg, from 2027 it will cover Ozempic and Mounjaro at no cost to employees with type 2 diabetes, with prior authorization, but not for weight loss.
Meanwhile, evidence suggests GLP-1 drugs may offer benefits beyond weight loss:
- Better blood sugar control, which can reduce long-term diabetes complications.
- Lower risk of kidney disease progression and possibly neuropathy, but no clear benefit for diabetic eye disease.
- Reduced cravings in people with substance use problems, particularly alcohol.
- Possible mental health benefits in people with severe mental illness such as schizophrenia and bipolar disorder. This evidence is early and largely observational.
Generic versions of GLP-1 drugs are expected to ease access: generic semaglutide was approved by Health Canada in June 2026. Wider use will also mean more people experiencing drug-induced complications, which makes careful dosing and monitoring more important.
How do semaglutide, liraglutide and tirzepatide differ?
In medicine, higher doses and greater potency generally mean a stronger response and a higher risk of side effects. GLP-1RAs follow this rule. Injectable forms generally have a stronger effect than tablets. A faster response, meaning quicker weight loss and lower blood sugar, is associated with a higher risk of serious side effects such as gallstones, pancreatitis and, rarely, permanent vision loss. Your genetics play some role in your response, as do the drug type, formulation and dose.
| Drug | Brand names | Receptors | Starting dose | Titration and maximum dose |
|---|---|---|---|---|
| Semaglutide | Ozempic and Rybelsus (T2D); Wegovy (weight management) | GLP-1 | 0.25 mg once weekly for 4 weeks (injection) | Ozempic: increases to 0.5 mg, 1 mg, up to 2 mg weekly. Wegovy: 2.4 mg weekly; higher doses up to 7.2 mg studied |
| Liraglutide | Victoza (T2D); Saxenda (weight management) | GLP-1 | 0.6 mg once daily | Increased weekly; Saxenda maximum 3.0 mg daily |
| Tirzepatide | Mounjaro; Zepbound | GLP-1 and GIP | 2.5 mg once weekly | Increased every 4 weeks to a maximum of 15 mg weekly |
| Retatrutide | Not marketed yet | GLP-1, GIP and glucagon | 4 mg weekly | Maximum studied dose 12 mg weekly |
Because tirzepatide acts on two receptors, people tend to lose more weight on it than on semaglutide, but it is also associated with a higher risk of nausea and vomiting.
How much weight do people lose on GLP-1 medications?
Everyone starts from a different point, and absolute weight loss depends on body composition and total mass. A key problem with GLP-1 drugs is that weight loss comes not only from fat but also from lean muscle. Losing too much weight without proper lifestyle changes, including exercise and diet composition, greatly increases the risk of complications. These include gastrointestinal obstruction (especially in older adults), gallstones, and cosmetic changes such as skin sagging in the face and in areas that store more fat. Choosing the most potent medication first and escalating the dose rapidly can significantly increase these risks.
Average weight loss in major clinical trials
| Drug | Dose studied | Average weight loss | Trial | Duration (weeks) |
|---|---|---|---|---|
| Liraglutide (Saxenda) | 3.0 mg daily | about 8% | SCALE | 56 |
| Semaglutide (Wegovy) | 2.4 mg weekly | about 15% | STEP 1 | 68 |
| Tirzepatide (Zepbound, Mounjaro) | 15 mg weekly | about 21% | SURMOUNT-1 | 72 |
| Retatrutide | 4 mg, 9 mg and 12 mg weekly | about 25% (12 mg dose) | TRIUMPH and TRANSCEND-T2D | 80 |
Results are averages for the trial population and vary by person.
The main problem with GLP-1 drugs is that significant side effects lead many people to stop treatment, and weight is often regained within a year of stopping (Reiss et al., 2025), faster than after behavioural weight-loss programs (West et al., 2026). The goal should not be to lose weight fast, but to achieve a sustainable response and make lifestyle changes that also lower the risk of complications.
Which genes affect GLP-1 response and side effects?
Several genome-wide association studies of GLP-1 medication response and side effects have been published, including a large study using 23andMe data for 27,880 people (Su et al., Nature 2026). It found that the rate of weight loss is affected by variation in GLP1R, the gene that encodes the receptor these drugs target. Earlier laboratory studies also showed that variants in GLP1R and GIPR change the response to GLP-1RAs. A separate study linked a different GLP1R variant, rs6923761, and the ARRB1 p.Thr370Met variant, which is more common in people of Spanish descent, to greater HbA1c reduction.
The T allele at rs10305420 in GLP1R is carried by roughly 18% to 30% of the population. It is associated with lower body mass index (BMI) and lower T2D risk. The 23andMe study did not analyze HbA1c, so weight loss and HbA1c response are likely shaped by multiple GLP1R variants and ARRB1.
GLP-1 pharmacogenetic variants reported to date
| Gene | Variant | Reported association | Clinically actionable today? |
|---|---|---|---|
| GLP1R | rs10305420 | Rate of weight loss on GLP-1RAs; lower BMI in the general population [PMID: 40443355] | No |
| GLP1R | rs6923761 | Greater HbA1c reduction [PMID: 36528349] | No |
| ARRB1 | p.Thr370Met | Greater HbA1c reduction; more common in people of Spanish descent [PMID: 36528349] | No |
| GLP1R | rs9357296 | Nausea with semaglutide [PMID: 41951734] | No |
| GIPR | rs1800437 | Nausea and vomiting with tirzepatide; risk is additive with GLP1R risk alleles [PMID: 41951734] | No |
For semaglutide, the risk of nausea and vomiting is associated with two GLP1R variants. One is partly linked to the variant associated with weight loss, while rs9357296 is associated mainly with nausea. However, the combination of the two had only nominal statistical significance across the whole GLP-1RA class, so their predictive value is low and they are not clinically useful at this time.
Because tirzepatide targets both the GLP-1 and GIP receptors, adding the GIPR variant rs1800437 increased statistical power to detect nausea and vomiting risk with that drug. The risk is additive: a small fraction of people with four risk alleles across GLP1R and GIPR have more than a 14-fold higher risk of vomiting on tirzepatide.
Can genetic testing predict serious GLP-1 side effects?
Not yet. The major limitation of these studies is that they have not validated associations with rarer but more severe side effects, namely pancreatitis, thyroid cancer and vision loss. Variants in CFTR and PRSS1 are known to confer risk of pancreatitis, and variants in RET confer risk of hereditary medullary thyroid cancer, which is why GLP-1 drugs carry black box warnings for people with a personal or family history of this cancer.
The genetic basis of GLP-1-associated vision loss is not established because the complication is exceptionally rare.
Is GLP-1 pharmacogenetic testing worth it?
At this time, pharmacogenetic testing for variants linked to weight loss and nausea has very limited clinical benefit. Some providers combine genetic testing with dietary counselling, which is often the most useful part of such a service. If you are considering a test, look for one that:
- is transparent about the evidence behind each variant and does not promise to pick your best drug;
- includes interpretation by a pharmacist or clinician, not just a report.
What does this mean for you?
- Talk with your prescriber or pharmacist about starting dose and how quickly to increase it. Slower escalation is associated with fewer side effects.
- Support lean muscle with adequate protein and resistance exercise.
- Contact your healthcare team promptly for severe abdominal pain, persistent vomiting or any change in vision.
- Do not choose or change a GLP-1 drug based on a genetic test result alone.
Frequently asked questions
Can a genetic test predict whether Ozempic or Wegovy will work for me?
Not reliably. Variants in the GLP1R gene, such as rs10305420, are associated with differences in weight loss, but the effect is modest. The drug, dose, formulation, adherence and lifestyle matter more. No GLP-1 genetic test has been validated to guide drug choice or dosing.
Which genes affect GLP-1 side effects such as nausea and vomiting?
Variants in GLP1R (including rs9357296) are associated with nausea on semaglutide, and a variant in GIPR (rs1800437) adds to the risk with tirzepatide. In one study, people carrying four risk alleles across GLP1R and GIPR had a higher risk of vomiting on tirzepatide, but only a small fraction of people carry that combination.
Is tirzepatide (Mounjaro, Zepbound) stronger than semaglutide (Ozempic, Wegovy)?
Tirzepatide activates both the GLP-1 and GIP receptors and, in clinical trials, produced greater average weight loss than semaglutide. It is also associated with a higher risk of nausea and vomiting. The right choice depends on your health, tolerance and coverage, not on genetics alone.
Can genetic testing predict serious GLP-1 side effects like pancreatitis or thyroid cancer?
Not at present. Variants in CFTR and PRSS1 are linked to pancreatitis risk and RET variants to hereditary thyroid cancer, but GLP-1-specific genetic risk prediction has not been validated. Vision loss is too rare to have an established genetic basis. Tell your prescriber about any personal or family history of these conditions.
Will my insurer cover or require a GLP-1 genetic test?
Some insurers are exploring whether genetic testing could help determine eligibility for GLP-1 coverage, but there is no established requirement and coverage varies by plan. Check with your insurer and prescriber before paying for a test.
How can I reduce GLP-1 side effects?
The main strategies are gradual dose escalation guided by your prescriber or pharmacist, dietary counselling, adequate protein and regular exercise. Starting with the most potent drug and increasing the dose quickly raises the risk of complications. Genetic testing does not currently replace these steps.
Medical disclaimer: This article is for general education and is not medical advice. Do not start, stop or change any medication without talking to your physician or pharmacist.
References
Reiss AR et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408.
West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304.
Su QJ, Ashenhurst JR, Xu W, et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026;653:770-775.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373:11-22.
Dawed AY et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2023;11(1):33-41.
Schmitz SH. Beyond Percentage of Weight Lost — Protecting Participants in Obesity Trials. N Engl J Med. 2026;395:1355-1357.
Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2604169.
Bloomberg. Pepsi, Starbucks, Cigna among companies dropping GLP-1 insurance benefits. September 23, 2026.
